Fresenius Kabi Tyenne tocilizumab injection recalled for glass particles
Fresenius Kabi Tyenne injection recalled for glass particles
Fresenius Kabi recalled one lot of Tyenne (tocilizumab-aazg) Injection 400 mg/20 mL vials after discovering the product contains glass particles. The affected lot was distributed nationwide to hospitals, clinics, and distributors.
- If you are a healthcare facility with the affected lot (16UI07, expiration 08/2028), stop using it immediately and return all units to Fresenius Kabi.
- If you received this medication, contact your doctor or pharmacist to confirm whether you have the recalled lot.
- Report any symptoms such as pain, swelling, or inflammation at the infusion site to your healthcare provider immediately.
- Call Fresenius Kabi Quality Assurance at 1-866-716-2459 (Mon–Fri, 8 a.m.–5 p.m. CST) with questions about the recall.
Product photos
FOR IMMEDIATE RELEASE – August 10, 2026 – LAKE ZURICH, Ill.— Fresenius Kabi, an operating company of the Fresenius Group, is recalling one lot of Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL (20 mg/mL)20 mL vials to the user level. An internal investigation at the firm found the product to cont
Official notice
https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/fresenius-kabi-issues-nationwide-recall-tyenner-tocilizumab-aazg-injection-400-mg20-ml-vials-dueMore Fresenius Kabi recalls
Don't want to check this manually?
We email you a Sunday digest of new federal recalls relevant to parents — free, no credit card. Or upgrade to as-it-happens alerts for the brands you actually own.
Get the Sunday Brief